Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LY3650150 Clear all
Active, not recruiting Phase 4 Interventional

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

NCT07006792
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 11:28 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 18 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

NCT04146363
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
30
States / cities
Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

NCT04178967
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
40
States / cities
Scottsdale, Arizona • Rogers, Arkansas • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

NCT04392154
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
160
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT04250350
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

NCT04250337
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, Topical Corticosteroid
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
43
States / cities
Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

NCT05369403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Montgomery, Alabama • Phoenix, Arizona • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 5, 2026, 11:28 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

NCT06339008
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 5, 2026, 11:28 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Lebrikizumab, Placebo, Topical Corticosteroid (TCS)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

NCT04840901
View directory record Official record
Conditions
Healthy
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 2 Interventional Results available

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

NCT03443024
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
58
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

NCT06921759
View directory record Official record
Conditions
Atopic Hand and Foot Dermatitis
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Hollywood, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 5, 2026, 11:28 PM EDT
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

NCT05372419
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
36
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 5, 2026, 11:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

NCT04626297
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
85
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 5, 2026, 11:28 PM EDT